glofitamab
roche
['cart,(-cartitude)', 'lymsm', 'glofitamab', 'lymphoma', 'dlbcl']
congress #eha2022 | presents the latest data of glofitamab, cd20xcd3 bispecific, in patients with r/r dlbcl and a median of 3 pl, including #cartcell. the primary endpoint was met: fixed-duration treatment led to a 39.4% cr rate #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm